Could Crohn's disease treatment become more precise? | Diaceutics

Could Crohn’s disease treatment become more precise?

February 19th, 2018



Crohn’s disease is an inflammatory condition that affects the gastrointestinal tract and can cause symptoms including abdominal pain, diarrhoea, bleeding, joint pain, mouth sores, fatigue and weight loss. The cause is unknown but bacteria and the immune system are implicated and there is often a family connection. Factors such as genetics, stress, viruses or smoking are also linked. The disease is more prevalent in western industrialized nations, which suggests environmental factors or even dietary differences could be an influence. Unfortunately, there is no cure at present for over 5 million people worldwide suffering with Crohn’s disease, ulcerative colitis and other related forms of inflammatory bowel disease.  

Diagnostic testing for Crohn’s disease 

There are various methods to diagnose the condition, although a doctor is likely to use more than one for confirmation: 

  • Blood test to look for anaemia or infection 
  • Fecal testing to look for blood 
  • Colonoscopy to find inflammatory cells or take a biopsy 
  • CT scan to take images of the bowel 
  • MRI scan to examine the organs, small intestines, tissue and pelvic fistulas 
  • Capsule endoscopy which enables camera images to be taken inside the small intestine 
  • Balloon-assisted enteroscopy, for a more detailed examination of the small bowel 

Current therapies  

Existing therapies for Crohn’s disease are essentially anti-inflammatory drugs or antibiotics, and corticosteroids can tame flareups. Surgery to remove affected sections of the intestine or colon is also an option, especially if medication is failingPatients can also take immunomodulators and anti-TNF (tumor necrosis factor) agents. Although new therapy development is ongoing, it has not yet been linked to precision or personalized medicine and so doesn’t require a companion diagnostic. Patients are therefore prescribed medication designed to alleviate symptoms and maintain remission rather than target the cause of the illness.  

Microbiome, gut health and Crohn’s disease 

Perhaps the ultimate treatment for Crohn’s lies in precision medicine, where a personalized therapy is given to a patient at the right time. And the hope for this could lie in the gut, the organ at the centre of inflammatory bowel conditions.  

The gut is host to trillions of microbes, or the ‘microbiomea living soup of bacteria, viruses and fungi. This initially sounds like a bad thing, but this complex and varied environment is crucial to general healthIt plays a role in the development of the immune system and so has potential links to Crohn’s. Projects like British Gut are inviting the public to explore the role the microbiome has on wellbeing. The aim is to uncover the microbial content within the guts of British individuals. This data will tell us how our lifestyle choices and diet influence our microbiome and how we can alter it to reduce disease and other health related problems.”  

Other areas for research which could affect Crohn’s disease are the importance of foods that can raise the number of good bacteria, or probiotics, in the microbiome. A varied diet can provide these, and certain foods are natural sources, particularly those that are fermented, such as sauerkraut or kimchi.  

There has been no concluding research to link the microbiome to Crohn’s disease but 2017 research showed that the urease enzyme associated with waste material was more present in the gut of Crohn’s patients. Researchers removed a significant portion of the microbiome to eliminate this enzyme and replaced it with an influx of ‘good’ bacteria that helps to generate a healthier gut environment. It is possible that targeting this enzyme could be a more direct way to combat the disease in the future, leading to the prospect of Crohn’s becoming general medicine disease that is transformed by precision medicine.  

 

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn